Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 582 1199

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

polloboy Feb. 14 at 4:22 PM

$ERNA $OLB $RIME $SBEV $SEGG SBEV is a dogshit stock/company, does nothing but burn cash and investors money.

0 · Reply

walfofwallstreet Feb. 14 at 4:14 PM

Tuesday fire 🔥list🔥👀👀🐺 $SEGG 💵💵💵💵💵$5+ $ERNA 💵$1+ $RIME 💵💵💵💵💵💵💵$7+ $SBEV 💵$1+ $OLB 💵$1+ Happy Valentine’s Day ❤️🐺 Tuesday let’s go 💰💵💰 All my followers are making bank 🏦 You all gonna be rich 🤑

1 · Reply

updog1 Feb. 14 at 1:47 PM

$RIME $IVDA $QNCX $ERNA $NCI ok mr.top secret...gtfoh

1 · Reply

TeamBullish Feb. 14 at 1:39 PM

Team’s taking a swing position next week. Unfortunately can’t share with public due to complexity. Looking for at least one 10–30%+ ROI day trade per session as well. Market’s closed Monday, but we will run it up starting Tuesday. Dialed in and ready to deliver, stay tuned. O/w: $RIME $IVDA $QNCX $ERNA $NCI

4 · Reply

StopLossGhost Feb. 14 at 8:08 AM

$OLB Looks like I picked to be in the right ticker, beautiful close, expecting massive volume to come here next week. Also on w/l: $ERNA $SBEV $SEGG not bad got eyes.

0 · Reply

walfofwallstreet Feb. 14 at 5:12 AM

$SEGG $ERNA $SBEV $OLB $RIME 🚨🐺 ATTENTION EVERYONE, 👇👇👇🚨👀🐺 This is the ONLY account I have, the ONLY one with 👉17K followers. I DON’T have other ACCOUNTS or any GROUPS!! All the other ACCOUNTS or GROUPS are fake SCAMMERS copying my account. I NEVER add or contact ANY one of my followers for service or ask for money!! If anyone does that please make sure to block and delete that scammer! All my posts here ONLY on StockTwits for FREE! I’m trying to help everyone with my experience 🫶🫶🐺 Tuesday let’s go 💰💵💰🫶🐺 All my followers are making bank 🏦 You all gonna be rich 🤑

2 · Reply

2tacos_plis Feb. 14 at 1:59 AM

$ERNA Holy shnykies😅! I tossed my hat in the ring this morning, picking up 2k shares at .28$ a share. Then exploded after hours, leaving us in primo shape come Tuesday morning. Can’t wait! Wowzers🤪!

0 · Reply

Bullbear1010101 Feb. 14 at 1:56 AM

$ERNA up 54 percent AH. dont trust it too much yet

0 · Reply

DaBullRunner Feb. 14 at 1:47 AM

What a way to end the week Hope you all had a great day as well! If you’re reading this just know that there are opportunities to make LIFE CHANGING gains EVERY DAY Bull market, Bear market… it doesn’t matter This market lately is designed to have 100% runners almost consistently You just need to know how to play the game and be in the know BEFORE the crowd And doing this for well over 20 years has given me the tools to understand the market behavior You seen my results I have NOTHING to prove Now my focus shifts to YOU I want to CHANGE lives I have changed many lives There is no feeling like it And I’m here to do it again So LETS GO!!!!!!!!! I wish each one of you reading this a successful and healthy new year, and beyond ❤️ $ERNA $RIME $OCUL $NCI $LFS see you all on Tuesday!

4 · Reply

peepthestamp Feb. 14 at 1:47 AM

$ERNA

0 · Reply

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Feb 3, 2026, 8:45 AM EST - 11 days ago

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Jan 27, 2026, 8:45 AM EST - 18 days ago

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Jan 6, 2026, 8:15 AM EST - 5 weeks ago

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Dec 8, 2025, 8:30 AM EST - 2 months ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Dec 3, 2025, 8:30 AM EST - 2 months ago

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 2, 2025, 8:50 AM EST - 2 months ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Nov 11, 2025, 7:00 AM EST - 3 months ago

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov 10, 2025, 8:35 AM EST - 3 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 6, 2025, 9:15 AM EST - 3 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Oct 29, 2025, 8:33 AM EDT - 3 months ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 1, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Sep 29, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 17, 2025, 8:30 AM EDT - 5 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 10, 2025, 8:30 AM EDT - 5 months ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 3, 2025, 9:30 AM EDT - 5 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Jul 9, 2025, 8:30 AM EDT - 7 months ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 25, 2025, 8:30 AM EDT - 8 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 24, 2025, 8:30 AM EDT - 8 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 10, 2025, 9:30 AM EDT - 8 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

May 28, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 14, 2025, 8:30 AM EDT - 9 months ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 8, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 29, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 10 months ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 3, 2025, 8:55 AM EDT - 11 months ago

Ernexa Therapeutics Closes New Funding Round

Feb 26, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Jan 14, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 9, 2025, 7:30 AM EST - 1 year ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

May 10, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 8, 2024, 9:31 AM EDT - 1 year ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Feb 20, 2024, 8:30 AM EST - 2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 14, 2023, 6:56 PM EST - 2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

May 24, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 17, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 3 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023, 7:30 AM EDT - 3 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Apr 11, 2023, 8:00 AM EDT - 3 years ago

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Mar 28, 2023, 8:30 AM EDT - 3 years ago

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Mar 20, 2023, 4:10 PM EDT - 3 years ago

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Feb 22, 2023, 8:00 AM EST - 3 years ago

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

polloboy Feb. 14 at 4:22 PM

$ERNA $OLB $RIME $SBEV $SEGG SBEV is a dogshit stock/company, does nothing but burn cash and investors money.

0 · Reply

walfofwallstreet Feb. 14 at 4:14 PM

1 · Reply

updog1 Feb. 14 at 1:47 PM

$RIME $IVDA $QNCX $ERNA $NCI ok mr.top secret...gtfoh

1 · Reply

TeamBullish Feb. 14 at 1:39 PM

4 · Reply

StopLossGhost Feb. 14 at 8:08 AM

$OLB Looks like I picked to be in the right ticker, beautiful close, expecting massive volume to come here next week. Also on w/l: $ERNA $SBEV $SEGG not bad got eyes.

0 · Reply

walfofwallstreet Feb. 14 at 5:12 AM

2 · Reply

2tacos_plis Feb. 14 at 1:59 AM

0 · Reply

Bullbear1010101 Feb. 14 at 1:56 AM

$ERNA up 54 percent AH. dont trust it too much yet

0 · Reply

DaBullRunner Feb. 14 at 1:47 AM

4 · Reply

peepthestamp Feb. 14 at 1:47 AM

$ERNA

0 · Reply

TheswingBull Feb. 14 at 1:29 AM

My top watches for Tuesday of next week: $OLB 💎 $RIME $ERNA $SEGG $FRGT Lets bank next week and have a great long weekend.

1 · Reply

CodexBlade Feb. 14 at 1:25 AM

OLB 💎 What a close! Next week is going to be big here. Make sure to keep OLB on ur watch if u haven't added, Pennies have been hot and I believe we continue the trend into next week as well. OLB has the look and Setup to see a parabolic move from here on. $ERNA $CHOW $SGN $BRTX paid this week.

0 · Reply

topstockalerts Feb. 14 at 1:18 AM

After Hours Top Gainers $ERNA $RIME $OCUL $LFS $NCI

0 · Reply

DaBullRunner Feb. 14 at 12:58 AM

$ERNA another one I will be watching for Tuesday

0 · Reply

Stockstock800 Feb. 14 at 12:50 AM

$ERNA

0 · Reply

walfofwallstreet Feb. 14 at 12:50 AM

Into the close fire 🔥list🔥👀👀🐺 $SEGG $ERNA $RIME $SBEV $OLB Stay tuned everyone 👀🐺🐺🐺 All my followers are making bank 🏦 You all gonna be rich 🤑

1 · Reply

Paraboljoker Feb. 14 at 12:50 AM

$CXAI Next 0.20 penny to go nuts? $ERNA $WORX $IVDA theme

0 · Reply

Bullishmenaq Feb. 14 at 12:48 AM

$ERNA 0.68 warrant

1 · Reply

GorillaDrill Feb. 14 at 12:44 AM

•hey guys ticker IBG could set up for a massive squeeze next week. SMX ran on 1 mil float IBG has 580k float, put IBG on your watchlist. IBG next week big squeeze watch merger news took a big position. $ERNA $RIME $EGG $OCUL <<<

0 · Reply

Game_Day Feb. 14 at 12:43 AM

$ERNA 🙌

0 · Reply

CodexBlade Feb. 14 at 12:40 AM

OLB 🚨Lot of big eyes are on this and loaded up. Low float+ 0 shares to borrow and Fits the penny theme. More folks are starting to find OLB.🚨🚨 Don't miss out bulls. Gapper next week! .70+ potential. Lets go @DaBullRunner OLB to the moon. $RIME $SEGG $FRGT $ERNA nice.

0 · Reply

CodexBlade Feb. 14 at 12:23 AM

OLB 🚨is setting up nicely for a parabolic move. Been grinding up all day and pressure is building. Low float+ 0 shares to borrow and Fits the penny theme. More folks are starting to find OLB.🚨🚨 Don't miss out bulls. Gapper next week! .70+ potential. $RIME $ERNA $FRGT nice day

0 · Reply

Market Cap	1.43M
Revenue (ttm)	580,000.00
Net Income (ttm)	-44.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,679.31%
Debt to Equity Ratio	0.00

Volume	359,085
Avg Vol	12,707,749
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	48%
Beta	4.47
Analysts	Hold
Price Target	N/A